MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)
Publication
, Conference
Angevin, E; Strickler, J; Weekes, C; Heist, R; Morgensztern, D; Fan, X; Olyaie, O; Motwani, M; Afar, D; Naumovski, L; Kelly, K
Published in: Journal of Thoracic Oncology
January 2017
Duke Scholars
Published In
Journal of Thoracic Oncology
DOI
ISSN
1556-0864
Publication Date
January 2017
Volume
12
Issue
1
Start / End Page
S395 / S396
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Angevin, E., Strickler, J., Weekes, C., Heist, R., Morgensztern, D., Fan, X., … Kelly, K. (2017). MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC). In Journal of Thoracic Oncology (Vol. 12, pp. S395–S396). Elsevier BV. https://doi.org/10.1016/j.jtho.2016.11.449
Angevin, Eric, John Strickler, Colin Weekes, Rebecca Heist, Daniel Morgensztern, Xiaolin Fan, Ozzie Olyaie, et al. “MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC).” In Journal of Thoracic Oncology, 12:S395–96. Elsevier BV, 2017. https://doi.org/10.1016/j.jtho.2016.11.449.
Angevin E, Strickler J, Weekes C, Heist R, Morgensztern D, Fan X, et al. MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC). In: Journal of Thoracic Oncology. Elsevier BV; 2017. p. S395–6.
Angevin, Eric, et al. “MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC).” Journal of Thoracic Oncology, vol. 12, no. 1, Elsevier BV, 2017, pp. S395–96. Crossref, doi:10.1016/j.jtho.2016.11.449.
Angevin E, Strickler J, Weekes C, Heist R, Morgensztern D, Fan X, Olyaie O, Motwani M, Afar D, Naumovski L, Kelly K. MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. Elsevier BV; 2017. p. S395–S396.
Published In
Journal of Thoracic Oncology
DOI
ISSN
1556-0864
Publication Date
January 2017
Volume
12
Issue
1
Start / End Page
S395 / S396
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology